Local treatment of malignant brain tumors using implantable chemotherapeutic polymers

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 3, Issue 5, 2005, Pages 721-728

  Gallia, Gary L ^a   Brem, Steven ^b   Brem, Henry ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Brain tumor; Carmustine; Chemotherapy; Drug delivery; Gliadel ; Glioblastoma; Glioma; Polymer

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; CARMUSTINE; GLIADEL WAFER; INTERLEUKIN 13; POLYMER; TEMOZOLAMIDE; UNCLASSIFIED DRUG; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BIOMATERIAL;

ABSENCE OF SIDE EFFECTS; ARTICLE; BIODEGRADABLE IMPLANT; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BRAIN TUMOR; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLIOBLASTOMA; HUMAN; SURGICAL TECHNIQUE; BIOREMEDIATION; GLIOMA; PROSTHESES AND ORTHOSES; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOCOMPATIBLE MATERIALS; BIODEGRADATION, ENVIRONMENTAL; BRAIN NEOPLASMS; CARMUSTINE; GLIOMA; HUMANS; POLYMERS; PROSTHESES AND IMPLANTS;

EID: 33644670748     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2005.0042     Document Type: Article

References (38)

1. Kleihues P, Cavenee WK (eds): Pathology and Genetics of Tumors of the Nervous System. Lyon, France: IARC Press; 2000.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. Lesniak MS, Brem H. Targeted therapy for brain tumors. Nature Rev Drug Discovery 2004;3:499-508,
4. Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature 1976;263:797-800.
5. Leong KW, D'Amore PD, Marletta M, et al. Bioerodible polyanhydrides as drug-carrier matrices. II. Biocompatibility and chemical reactivity. J Biomed Mater Res 1986;20:51-64.
6. Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983;52:997-1107.
7. Green SB, Byar DP, Walker MD, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983;67:121-132.
8. Brem H, Kader A, Epstein JI, et al. Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain. Selective Cancer Ther 1989;5:55-65.
9. Tamargo RJ, Epstein JI, Reinhard CS, et al. Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J Biomed Mater Res 1989;23:253-266.
10. Fung LK, Ewend MG, Sills A, et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 1998;58:672-684.
11. Grossman SA, Reinhard C, Colvin OM, et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 1992;76:640-647.
12. Tamargo RJ, Myseros JS, Epstein JI, et al. Interstitial chemotherapy of the 9L gliosarcoma: Controlled release polymers for drug delivery in the brain. Cancer Res 1993;53:329-333.
13. Brem H, Tamargo RJ, Olivi A et al. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 1994;80:283-290.
14. Brem H, Mahaley MS, Vick NA, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991;74:441-446.
15. Brem H, Piantadosi S, Burger PC. et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995;345:1008-1012.
16. Brem H, Ewend MG, Piantadosi S, et al. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neurooncol 1995;26:111-123.
17. Valtonen S, Timonen U, Toivanen P et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997;41:44-49.
18. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 2003;5:79-88.
19. Meldorf MG, Riddle V, Agarwal S, et al. Long term efficacy of the gliadel wafer in patients with glioblastoma multiforme. 2003 AANS Meeting Abstracts (Article ID# 17769).
20. Sipos EP, Tyler B, Piantadosi S, et al. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol 1997;39:383-389.
21. Olivi A, Grossman SA, Tatter S, et al. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS consortium trial. J Clin Oncol 2003;21:1845-1849.
22. Lang FF, Chang EL, Abi-Said D, et al. Metastatic Brain Tumors. In: Winn RH, eds. Youman's Neurological Surgery, 5th ed. Philadelphia, PA: Saunders; 2004:1077-1097.
23. Ewend MG, Williams JA, Tabassi K, et al. Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. Cancer Res 1996;56:5217-5223.
24. Ewend MG, Sampath P, Williams JA, et al. Local delivery of chemotherapy prolongs survival in experimental brain metastasis from breast carcinoma. Neurosurgery 1998;43:1185-1193.
25. Ewend MG, Brem S, Gilbert M, et al. Treating single brain metastasis with resection, placement of BCNU-polymer wafers, and radiation therapy. 2001 AANS Meeting Abstracts (Article ID# 13719).
26. Brem S, Staller A, Wotoczek-Obadia M, et al. Interstitial chemotherapy for local control of CNS metastases (Abstr #TA-06). Neuro-Oncology 2004;6:370-371.
27. Gerson SL. MGMT: Its role in cancer aetiology and cancer therapeutics. Nature Rev Cancer 2004;4:296-307.
28. 6-alkylguanine-DNA alkyltransferase activity in human brain and brain tumors. Carcinogenesis 1984;5:121-124.
29. Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996;56:783-788.
30. 6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosurea: a Southwest Oncology Group study. J Clin Oncol 1998;16:3310-3315.
31. 6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res 2000;6:3025-3031.
32. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2000;18:3522-3528.
33. 6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res 2000;60:6307-6310.
34. Rosenblum M, Weingart J, Dolan E, et al. Phase I study of Gliadel combined with a continuous intravenous infusion of O6-benzylguanine in patients with recurrent malignant glioma (Abstr #314). Proc Am Soc Clin Oncol 2002;21:79a.
35. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
36. Gururangan S, Cokgor L, Rich JN, et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-Oncology 2001;3:246-250.
37. Larocca RV, Vitaz TW, Morassutti DJ, et al. A Phase II study of radiation with concomitant and then sequential temozolomide (TMZ) in patients (pts) with newly diagnosed supratentorial high grade malignant glioma (MG) who have undergone surgery with carmustine (BCNU) wafer insertion (Abstr #1547). Supp to J Clin Oncol ASCO Annual Meeting Proc 2005;23:125s.
38. Raza SM, Pradilla G, Legnani FG, et al. Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumors. Expert Opin Biol Ther 2005;5:477-494.